Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534886 | 0.89 | TRPA1 (0.42) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL1856265 | 0.82 | TAAR1 (0.52) | TRPA1TSHRHTR2ATAAR1DPP4 | |
| SCHEMBL1344877 | 0.81 | TSHR (0.50) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL9451798 | 0.80 | ESR2 (0.41) | ESR1ESR2ALDH1A1CYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL7863498 | 0.80 | TAAR1 (0.50) | TRPA1TSHRESR1ESR2HTR2A | |
| SCHEMBL23199874 | 0.77 | TSHR (0.52) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL1094363 | 0.77 | TSHR (0.52) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL3240433 | 0.77 | TSHR (0.46) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL10402490 | 0.77 | TRPA1 (0.46) | TRPA1TSHRESR1ESR2ALDH1A1 | |
| SCHEMBL31261480 | 0.77 | TSHR (0.52) | TRPA1TSHRESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1857471-B1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | MITSUI CHEMICALS INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-7960305-B2 | a mixture of a phosphazenium compound such as tetrakis[tris(dimethylamino)phosphoranylideneamino]phosphonium chloride, transition metal halides and an organic halogen compound as an activator, used for addition homo/copolymerization; living polymers | MITSUI CHEMICALS, INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-101128491-B | Polymerization catalyst composition and method for producing polymer | MITSUI CHEMICALS INC | 2010-09-08 | — | — | CN | disclosed |
| US-20080177014-A1 | Polymerization Catalyst Composition and Process for Production of Polymer | MITSUI CHEMICALS, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| CN-101128491-A | Polymerization catalyst composition and method for producing polymer | MITSUI CHEMICALS INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1857471-A1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | Mitsui Chemicals, Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
| EP-0393534-B1 | Pharmaceutically active pteridine derivatives | ROEHM GMBH (DE) | 1995-07-12 | — | — | EP | disclosed |
| US-5124326-A | Antiarrhythmic, hypotensive agents; diuretics | ROEHM GMBH CHEMISCHE FABRIK (DE) | 1992-06-23 | — | — | US | disclosed |
| EP-0393534-A2 | Pharmaceutically active pteridine derivatives | RÖHM GMBH (DE) | 1990-10-24 | — | — | EP | disclosed |
| EP-0195817-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SCHERING CORP (US) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986001803-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | TRPA1 3978/4885TSHR 1834/4885ESR1 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.